



Substitute for form 1449/PTO
(Revised 07/2005)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 6

Complete if Known

Application Number 10/805,977
Filing Date March 22, 2004
First Named Inventor Fraser et al.
Group Art Unit 1614
Examiner Name SPIVACK
Attorney Docket Number 046562/274660

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
PS	56	US-2007/0060652	03-15-2007	Fraser, et al.	
PS	57	US- 2004/0142034	07-02-2004	Thor et al.	
PS	58	US- 2006-0188575	08-24-2006	Thor et al.	
PS	59	US- 2002-0077319	06-20-2002	Mylari, Banavara L.	
PS	60	US- 2005-0272719	12-08-2005	Landau et al.	
PS	61	US- 2002-0198136 A1	12-26-2002	Mak et al.	
PS	62	US- 2004-0037881 A1	02-26-2004	Guittard et al.	
PS	63	US- 5,738,873	04-18-1998	Bleiweiss et al.	
PS	64	US- 5,610,136	03-1997	McMichael, John	
PS	65	US- 5,116,615	05-1992	Gokcen et al.	
PS	66	US- 5,180,715	01-1993	Parsons, C. Lowell	
PS	67	US- 6,090,856	07-2000	Sasaki, Yasuo	
PS	68	US- 6,150,396	11-2000	Iyengar et al.	
PS	69	US- 6,066,643	05-2000	Perry, Kenneth Wayne	
PS	70	US- 5,677,326	10-1997	Tsuchiya et al.	
PS	71	US- 6,200,991	03-2001	Courtemanche et al.	
PS	72	US- 6,319,920	11-2001	Caroon et al.	
PS	73	US- 6,316,638	11-13-2001	Bryans et al.	
PS	74	US- 6,489,352	12-03-2002	Bryans et al.	
	75	US Appl. 60/160,725		Bryans	

Examiner
Signature

Phyllis Spivack

Date
Considered

2/8/08

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/805,977	
				Filing Date		March 22, 2004	
				First Named Inventor		Fraser et al.	
				Group Art Unit		1614	
Examiner Name		SPIVACK					
Sheet	3	of	6	Attorney Docket Number 046562/274660			
OTHER DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, dc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			English Language Translation Attached		
PS	84	Abrams, Expert Opin. Pharmacother., 2001, 2(10), 1685-1701.					
PS	85	Database Caplus on STN (Columbus, OH, USA) DN: 2001:560196, "Sphincter and Bladder Dysfunction", abstract, Joseph et al., Revue Neurologique (Paris), (September 2001), Vol. 157, No. 8-9, pp. 1051-1059.					
PS	86	The Merck Index, 12 th edition, Merck & Col (1996) page 733.					
PS	87	ANTONIO CARBONE, et al., "The Use of Gabapentine in the Treatment of Neurogenic Detrusor Overactivity: Preliminary Urodynamic and Clinical Results," Neurourology and Urodynamics, 2002, Vol. 21(4), pp. 336-337.					
PS	88	"Hyperreflexia" and "Incontinence". Stedman's Medical Dictionary (Twenty Second Edition), Williams and Wilkins Company, 1972, pages. 604 and 626.					
PS	89	Osol A. (Editor). Remington's Pharmaceutical Sciences (Sixteenth Edition). Mack Publishing, 1980, pages 669-671.					
PS	90	IGAWA, Y, et al., "Effects of Gaba-Receptor Stimulation and Blockade on Micturition in Normal Rats and Rats with Bladder outflow Obstruction," The Journal of Urology, 1993, pp. 537-542, Vol. 150.					
PS	91	BERTRAND, S. et al., "The Anticonvulsant, Antihyperalgesic Agent Gabapentin Is an Agonist at Brian γ -Aminobutyric Acid Type B Receptors Negatively Coupled to Voltage-Dependent Calcium Channels," The Journal of Pharmacology and Experimental Therapeutics, 2001, pp. 15-24, Vol. 298(1).					
PS	92	Bertrand et al. "Gabapentin Actions on Kir3 Currents and N-type Ca ²⁺ Channels via GABA-B Receptors in Hippocampal Pyramidal Cells." Synapse, 50:95-109, 2003.					
PS	93	MEGSON, I.L., "Nitric Oxide Donor Drugs," Drugs of the Future, 2000, pp. 701-715, Vol. 25(7).					
PS	94	NILVEBRANT, L., "Tolterodine and its Active 5-Hydroxymethyl Metabolite: Pure Muscarinic Receptor Antagonists," Pharmacology & Toxicology, 2002, pp. 260-267, Vol. 90.					
PS	95	SEGUCHI, et al., "Expression of beta 3-Adrenoceptors in Rat Detrusor Smooth Muscle," The Journal of Urology, 1998, pp. 2197-2201, Vol. 159(6).					

Examiner Signature	P. Spivack	Date Considered	2/8/08
--------------------	------------	-----------------	--------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/805,977		
		Filing Date	March 22, 2004		
		First Named Inventor	Fraser et al.		
		Group Art Unit	1614		
		Examiner Name	SPIVACK		
Sheet	4	of	6	Attorney Docket Number	046562/274660
OTHER DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.			English Language Translation Attached
PS	96	BETTLER, B., et al., "Molecular Structure and Physiological Functions of GABA _B Receptors," <i>Physiol. Rev.</i> , 2004, pp. 835-867, Vol. 84			
PS	97	CHENG, J. and L. CHIOU, "Mechanisms of the Antinociceptive Action of Gabapentin," <i>J. Pharmacol. Sci.</i> , 2006, pp. 471-486, Vol. 100			
PS	98	CHENG, J., et al., "Does Gabapentin Act as an Agonist at Native GABA _B Receptors?" <i>J. Biomed. Sci.</i> , 2004, pp. 346-55, Vol. 11			
PS	99	CUI, M., et al., "In Vitro Characterization of GABAB Receptors and Gabapentin Effect," Program No. 869.15, 2002 Abstract Viewer/Itinerary Planner, Washington, DC: Society for Neuroscience, 2002, Online			
PS	100	ECKSTEIN-LUDWIG, U., et al., "Inhibition of Uptake, Steady-state Currents, and Transient Charge Movements Generated by the Neuronal GABA Transporter by Various Anticonvulsant Drugs," <i>Br. J. Pharmacol.</i> , 1999, pp. 92-102, Vol. 128			
PS	101	GALVEZ, T., et al., "Mutagenesis and Modeling of the GABA _B Receptor Extracellular Domain Support a Venus Flytrap Mechanism for Ligand Binding," <i>J. Biol. Chem.</i> , 1999, pp. 13362-13369, Vol. 274(19)			
PS	102	GALVEZ, T., et al., "Ca ²⁺ Requirement for High-Affinity γ -Aminobutyric Acid (GABA) Binding at GABA _B Receptors: Involvement of Serine 269 of the GABA _B R1 Subunit," <i>Mol. Pharmacol.</i> , 2000, pp. 419-426, Vol. 57			
PS	103	GALVEZ, T., et al., "Mapping the Agonist-binding Site of GABA _B Type 1 Subunit Sheds Light on the Activation Process of GABA _B Receptors," <i>J. Biol. Chem.</i> , 2000, pp. 41166-41174, Vol. 275(52)			
PS	104	GREEN, A. et al., "Characterization of [³ H]-CGP54626A Binding to Heterodimeric GABA _B Receptors Stably Expressed in Mammalian Cells," <i>Br. J. Pharmacol.</i> , 2000, pp. 1766-1774, Vol. 131			
PS	105	KAUPMANN, K., et al., "GABA _B -receptor Subtypes Assemble into Functional Heteromeric Complexes," <i>Nature</i> , 1998, pp. 683-687, Vol. 396			
PS	106	KUNER, R., et al., "Role of Heteromer Formation in GABAB Receptor Function," <i>Science</i> , 1999, pp. 74-77, Vol. 283(74)			
PS	107	MALITSCHKE, B., et al., "The N-Terminal Domain of γ -Aminobutyric Acid _B Receptors is Sufficient to Specify Agonist and Antagonist Binding," <i>Mol. Pharmacol.</i> , 1999, pp. 448-454, Vol. 56			
PS	108	MANEUF, Y., et al., "Drugs of the Future: Review 'Cellular and Molecular Action of the Putative GABA-mimetic, Gabapentin,'" <i>Cell Mol Life Sci.</i> , 2003, pp. 742-750, Vol. 60			
Examiner Signature	P. SPVACK			Date Considered	2/8/08

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005)		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/805,977
		Filing Date	March 22, 2004
		First Named Inventor	Fraser et al.
		Group Art Unit	1614
		Examiner Name	SPIVACK
Sheet	5	of	6
Attorney Docket Number 046562/274660			
OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
PS	109	MANEUF, Y., <i>et al.</i> , "α2δ and the Mechanism of Action of Gabapentin in the Treatment of Pain," <i>Semin. Cell Dev. Biol.</i> , 2006, doi:10.1016/j.semcdb.2006.09.003 [Epub ahead of print]	
PS	110	MARTIN, D., <i>et al.</i> , "Gabapentin-mediated Inhibition of Voltage-activated CA ²⁺ Channel Currents in Cultured Sensory Neurons is Dependent on Culture Conditions and Channel Subunit Expression," <i>Neuropharmacology</i> , 2002, pp. 353-366, Vol. 42	
PS	111	NEURONTIN® (Gabapentin) Prescription Drug Information Label, October 12, 2000	
PS	112	NG, G., <i>et al.</i> , "γ-Aminobutyric Acid Type B Receptors with Specific Heterodimer Composition and Postsynaptic Actions in Hippocampal Neurons are Targets of Anticonvulsant Gabapentin Action," <i>Mol. Pharmacol.</i> , 2001, pp. 144-152, Vol. 59(1)	
PS	113	PATEL, S., <i>et al.</i> , "The Effects of GABA _B Agonists and Gabapentin on Mechanical Hyperalgesia in Models of Neuropathic and Inflammatory Pain in the Rat," <i>Pain</i> , 2001, pp. 217-226, Vol. 90	
PS	114	ROSE, M.A. and P.C.A. KAM, "Gabapentin: Pharmacology and its Use in Pain Management," <i>Anaesthesia</i> , 2002, pp. 451-462, Vol. 57	
	115	SILLS, G.J., Commentary on "Gabapentin Activates Presynaptic GABA _B Heteroreceptors in Rat Cortical Slices," <i>Epilepsy Curr.</i> , 2005, pp. 75-77, Vol. 5	
PS	116	SILLS, G.J., "The Mechanisms of Action of Gabapentin and Pregabalin," <i>Curr. Opin. Pharmacol.</i> , 2006, pp. 108-113, Vol. 6	
PS	117	SUMAN-CHAUHAN, N., <i>et al.</i> , "Characterisation of [³ H]gabapentin Binding to a Novel Site in Rat Brain: Homogenate Binding Studies," <i>Eur. J. Pharmacol.</i> , 1993, pp. 293-301, Vol. 244	
PS	118	SUTTON, K., <i>et al.</i> , "Gabapentin Inhibits High-threshold Calcium Channel Currents in Cultured Rat Dorsal Root Ganglion Neurons," <i>Br. J. Pharmacol.</i> , 2002, pp. 257-265, Vol. 135	
PS	119	TAYLOR, C.P., "Mechanisms of Action of Gabapentin," <i>Rev. Neurol. (Paris)</i> , 1997, pp. 39-45, Vol. 15	
PS	120	TAYLOR, C., <i>et al.</i> , "A Summary of Mechanistic Hypotheses of Gabapentin Pharmacology," <i>Epilepsy Res.</i> , 1998, pp. 233-249, Vol. 29	
PS	121	WHEELER, G., "Gabapentin," <i>Curr. Opin. Investig. Drugs</i> , 2002, pp. 470-477, Vol. 3(3)	
PS	122	WHITE, J., <i>et al.</i> , "Heterodimerization is Required for the Formation of a Functional GABA _B Receptor," <i>Nature</i> , 1998, pp. 679-682, Vol. 396	
Examiner Signature	P. Spivack		Date Considered 2/8/08

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/805,977		
		Filing Date	March 22, 2004		
		First Named Inventor	Fraser et al.		
		Group Art Unit	1614		
		Examiner Name	SPIVACK		
Sheet	6	of	6	Attorney Docket Number	046562/274660
OTHER DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.			English Language Translation Attached
PS	123	KATZUNG, B.G., "Basic and Clinical Pharmacology, 8th Ed.," Lange Medical Books, 2001, pp. 457-459, McGraw Hill, U.S.			
PS	124	"Hypertrophy". Stedman's Medical Dictionary (Twenty Second Edition). The Williams and Wilkins Company, 1972. p.605.			
PS	125	TANAKA, N., et al., "Relationship Between Stereochemistry and the β 3-Adrenoceptor Agonistic Activity of 4'-Hydroxynorephedrine Derivative as an Agent for Treatment of Frequent Urination and Urinary Incontinence," J. Med Chem., 2003, pp. 105-112, Vol. 46.			
PS	126	WANG, P.S., et al., "Urinary Antispasmodic Use and the Risks of Ventricular Arrhythmia and Sudden Death in Older Patients," JAGS, 2002, pp. 117-124, Vol. 50.			
PS	127	Fry et al. "Bladder Instability and Detrusor Smooth Muscle Function." Experimental Physiology, 1999, 84:161-169.			
Examiner Signature	P. Spivack			Date Considered	2/8/08

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

11/28/07

Complete if Known

Application Number	10/805,977
Filing Date	March 22, 2004
First Named Inventor	Fraser et al.
Art Unit	1614
Examiner Name	Spivack, Phyllis
Attorney Docket Number	046562/274660

OTHER DOCUMENTS

[illegible]

Examiner Signature	<i>Paulis Spivack</i>	Date Considered	<i>2/8/08</i>
-----------------------	-----------------------	--------------------	---------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.